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ABSTRACT  37 
 38 
Background:  39 
Peanut allergy is a severe and increasingly frequent disease with high medical, psychosocial and 40 
economical burden for affected patients. A causal, safe and effective therapy is not available.  41 
Objective: 42 
We aimed to develop an immunogenic, protective and non-reactogenic vaccine candidate against 43 
peanut allergy based on Virus-like Particles (VLPs) coupled to single peanut allergens.  44 
Methods: 45 
To generate vaccine candidates, extracts of roasted peanut (Ara R) or the single allergens Ara h 1 46 
or Ara h 2 were coupled to immunologically optimized Cucumber Mosaic Virus-derived VLPs 47 
(CuMVtt). BALB/c mice were sensitized intraperitoneally with peanut extract absorbed to Alum. 48 
Immunotherapy consisted of one single subcutaneous injection of CuMVtt coupled to Ara R, Ara 49 
h 1 or Ara h 2.  50 
Results: 51 
The vaccines CuMVtt-Ara R, CuMVtt-Ara h 1 and CuMVtt-Ara h 2 protected peanut sensitized 52 
mice against anaphylaxis after i.v. challenge with the whole peanut extract. Vaccines did not 53 
cause allergic reactions in sensitized mice. CuMVtt-Ara h 1 was able to induce specific IgG 54 
antibodies, diminished local reactions after skin-prick-tests and reduced the infiltration of the 55 
gastrointestinal tract by eosinophils and mast cells after oral challenge with peanut. The ability of 56 
CuMVtt-Ara h 1 to protect against challenge with the whole extract was mediated by IgG, as 57 
shown via passive IgG transfer. FcγRIIb was required for protection, indicating that immune-58 
complexes with single allergens were able to block the allergic response against the whole 59 
extract, consisting of a complex allergen mixture.  60 
Conclusion: 61 
Our data suggest that vaccination using single peanut allergens displayed on CuMVtt may 62 
represent a novel and safe therapy against peanut allergy. 63 
  64 
CAPSULE SUMMARY 65 
 66 
Severe peanut allergy remains a critical pathology in clinical everyday life. In this preclinical 67 
study a vaccine based on Virus-Like-Particles displaying single major peanut allergens is 68 
presented as a possible safe and effective therapy against peanut allergy. 69 
 70 
 71 
KEY MESSAGES 72 
 73 
- Peanut allergy is a disease with increasing prevalence and avoidance of peanut is difficult to 74 
achieve 75 
- Oral immunotherapy is effective, but time consuming and potentially dangerous for severely 76 
allergic patients 77 
- An active vaccination based on engineered Virus-Like-Particles displaying single major peanut 78 
allergens generates protective IgG antibodies in a mouse model for peanut allergy 79 
- Protection is FcγRIIb-dependent, showing the critical role of IgG-allergen immune complexes 80 
for protection against complex allergen mixtures 81 
 82 
 83 
 84 
ABBREVIATIONES  85 
 86 
VLPs: Viurs-like Particles 87 
Ara R: roasted peanut extract 88 
CuMVtt: Cucumber Mosaic Virus including tetanus toxin epitopes 89 
PA: peanut allergy 90 
OIT: oral immunotherapy 91 
SLIT: sublingual immunotherapy 92 
EPIT: epicutaneous immunotherapy  93 
TLR: Toll-like receptor 94 
MCPT-1: mast cell protease-1 95 
DARPin: designed ankyrin repeat proteins 96 
 97 
 98 
 99 
100 
INTRODUCTION 101 
 102 
Peanut allergy (PA) is a severe disease and is the most frequent cause of anaphylactic reactions 103 
and death among food allergies. The prevalence of PA  in Western countries ranges between 1.4 104 
to 3 % in children and is increasing (1). The disease typically develops early in life and only in 105 
about 20% of cases an outgrow of the allergy is observed (2). The economic and psychosocial 106 
consequences of PA are important (3). Strict avoidance of peanut is the most common strategy 107 
used by allergic patients, but is difficult to achieve. In terms of prevention, a randomized 108 
controlled trial in infants at high risk to develop peanut allergy found that early peanut 109 
consumption reduced the risk in comparison to peanut avoidance (4). In contrast, another 110 
randomized controlled clinical trial in normal risk infants found that early peanut exposure had 111 
no significantly protective effect on the development of peanut allergy (5). Finally, an 112 
observational trial in newborns again indicated that early peanut exposure had a protective effect 113 
(6). 114 
In terms of therapy, several immunotherapy trials with peanut allergic patients have been 115 
performed, mainly using oral (OIT), sublingual (SLIT) and epicutaneous immunotherapy (EPIT) 116 
(7–9). These therapies showed beneficial effects on PA, but were associated with a long phase of 117 
desensitization (10). In addition, potentially dangerous systemic allergic reactions and disturbing 118 
gastrointestinal symptoms have been observed (11),(12). A recently published phase III clinical 119 
trial (13) investigating OIT showed positive results relating to desensitization against peanut, but 120 
patients with a history of severe anaphylaxis with bronchial asthma and chronic gastrointestinal 121 
symptoms were excluded in advance, similarly to previous trials (14). Thus, there is currently no 122 
causal, safe and ideally effective therapy of PA, especially for those patients with severe allergy.  123 
Peanuts contain a mixture of 12 allergens and numerous isoforms; considered as major allergens 124 
are Ara h 1 and Ara h 3 (members of the cupin superfamily) as well as Ara h 2 and Ara h 6 125 
(members of the prolamin superfamily) (15) although IgE specificities vary among peanut 126 
allergic patients.  127 
Most children with detectable peanut-specific IgE are not allergic to peanut (16). A previous 128 
study identified the central role of peanut specific IgG4 for clinical tolerance in sensitized but not 129 
allergic patients (17). The IgG4/IgE ratio to peanut was significantly greater in peanut sensitized 130 
but tolerant patients compared with that seen in allergic subjects, indicating that excess of IgG4 131 
could contribute to clinical tolerance. Direct competition of IgG4 with IgE for the allergen and 132 
binding of IgG4-allergen complexes to the inhibitory receptor FcγRIIb on mast cells and 133 
basophils are supposed to be responsible for protection. These findings were consistent with 134 
observations in patients after successful peanut immunotherapy. These patients show an increase 135 
of specific IgG4 levels most notably to the major allergen Ara h 2, suggesting that Ara h 2 is an 136 
important allergenic protein in peanut (18).  137 
Whether allergen immunotherapy works via rebalancing the T cell response or via induction of 138 
antibodies is a long standing debate (19). A protective effect against cat allergy through direct 139 
administration of two Fel d 1 specific IgG4 monoclonal antibodies has been demonstrated 140 
recently in a clinical study with cat allergic patients (20). IgG4 antibodies are thought to compete 141 
with IgE for Fel d 1 binding, thereby inhibiting the crosslinking of the FcεRI on mast cells and 142 
basophils. In addition, allergen-IgG immune complexes engage the inhibitory FcγRIIb, thereby 143 
blocking cellular activation. Based on these considerations, we postulate that a vaccine against 144 
peanut allergens able to induce a strong and specific IgG response may have the potential to 145 
protect peanut allergic patients.  146 
Virus-like particles (VLPs) are safe platforms for induction of protective antibodies and several 147 
VLP-based vaccines are commercially available including against Human Papilloma Virus and 148 
Hepatitis B Virus (21). In a previous study, a vaccine consisting of Qβ-derived VLPs coupled to 149 
the cat allergen Fel d 1 has been shown to be highly immunogenic and able to induce specific 150 
IgG antibodies in mice. Immunization of Fel d 1 sensitized mice with Qβ-Fel d 1 protected 151 
against anaphylaxis after challenge with Fel d 1 allergen (22). In a recent study, it has been 152 
shown that allergens displayed on Qβ-VLP are immunogenic but not reactogenic and fail to 153 
activate human mast cells (23). VLP could therefore constitute a platform to deliver allergens to 154 
peanut allergic patients in an immunogenic and effective but safe way.  155 
In the current study, we aimed to develop and test vaccine candidates against peanut allergy 156 
based on the immunologically optimized VLP derived from Cucumber Mosaic Virus (CuMVtt) 157 
(24). In addition to the immunogenic properties of other VLPs including the repetitive three-158 
dimensional scaffold (B cell activation) (25) and the RNA content (stimulation of TLR7 and 159 
TLR8), CuMVtt contains the a universal T cell epitope derived from the tetanus toxin (tt) 160 
genetically fused into the structure. The pre-existing T cell memory for tt is near universal in 161 
humans and incorporation of the tt epitope boosted T-cell response in randomly selected primary 162 
human T cells (24). 163 
Here, we tested the efficacy of vaccine candidates composed of CuMVtt coupled to the whole 164 
extract of roasted peanut or to the single major allergens Ara h 1 or Ara h 2 in a mouse model of 165 
peanut allergy and demonstrate strong immunogenicity and ability to protect against local and 166 
systemic allergic reactions to allergen extracts. We finally delineate the mechanism of action of 167 
the vaccines. 168 
169 
MATERIALS AND METHODS 170 
 171 
Production of peanut extract, Ara h 1, Ara h 2 172 
The extract of roasted peanut was obtained according to the protocol from Koppelmann et al. 173 
(26). Briefly, 10 g of roasted peanut kernels (roasted salted peanuts (Felix) produced by 174 
Intersnack, Poland) were manually ground with mortar and pestle in 20 mM Tris-HCl, 2 mM 175 
EDTA buffer (pH 8.2), the insoluble lipid part of peanut was removed through three low speed 176 
centrifugations (see supplementary figure S1 A).  177 
Ara h 1 enrichment and purification from native peanut extract was performed with Ammonium 178 
sulfate fractionations, anion-exchange and size-exclusion chromatography (see supplementary 179 
figure S1 B, C).  180 
Recombinant peanut antigen Ara h 2 was produced in E.coli C2566 cells transformed with  181 
pET42-Ara-h202-nhk. The biomass was sonicated in 10 ml buffer (20mM Tris/HCl  pH 7.5, 1 182 
mM EDTA, 0.1 mM PMSF, 0.1% TX-100, DNAse I (30 µg/10ml), RNAse (0.5 mg/10ml). 183 
Sonication of the cells was performed for 16 minutes (0.5 interval / 0.7 power, Hielscher 184 
UP200S). Additional 10 ml of the buffer were added, the suspension mixed on rotating mixer (10 185 
rpm at room temperature for 1 hour). Inclusion bodies were collected by centrifugation at 11000 186 
rpm for 30 min and washed with the same buffer. Next, insoluble Arah202-nhk pellets were 187 
solubilized in 10 ml of 6M guanidine-HCl containing 100 mM NaCl; 5 mM EDTA; 10 mM 188 
DTT; 20 mM Tris 8.5 and incubated at room temperature overnight. Then the sample was 189 
centrifuged (11000 rpm, 30 min) and slowly added to 110 ml refolding buffer (0.1M CAPS pH 190 
9.5, 0.9M arginine, 0.3mM reduced and 0.03mM oxidized glutathione). After overnight 191 
incubation at room temperature the mixture was dialyzed against 200 volumes of buffer 192 
containing 20 mM Tris-HCl, 50 mM NaCl (ON, +4 °C) using SpectraPor dialysis membrane 193 
(12-14 kDa). Refolded Arah202-nhk was diluted with 50 mM Tris-HCL (pH8.0), loaded onto 194 
Sepharose Q HP (XK16/20 column) and eluted with 1M NaCl in 50 mM Tris-HCl (pH 8.0). 195 
Arah202-nhk containing fractions were finally purified using Superdex 200 column (see 196 
supplementary figure S1 D).   197 
Ara h 1 and Ara h 2 were identified by anti-Ara h 1 and anti-Ara h 2 polyclonal antibodies 198 
(Indoor Biotechnologies, Charlottesville, VA, USA) on Western blots followed by incubation 199 
with Horseradish peroxidase (HRP)-conjugated secondary anti-rabbit IgG (Sigma-Aldrich,  200 
Staint-Loius, USA), see supplementary figure S1 B. 201 
Production of CuMVtt 202 
The production of CuMVtt was described in details in (24). Briefly,  RNA from CuVMtt-203 
infected lily leaves was isolated using TRI reagent (Sigma-Aldrich,  Staint-Loius, USA). For 204 
cDNA synthesis, OneStep RT-PCR kit (Qiagen, Venlo, Netherlands) was used. The 205 
corresponding PCR products were cloned into the pTZ57R/T vector (Fermentas, Vilnius, 206 
Lithuania). After sequencing, the cDNA of CuMV coat protein (CP) gene was then subcloned 207 
into the NcoI/HindIII sites of the pET28a(+) expression vector (Novagen, San Diego, USA), 208 
resulting in the expression plasmid pETCuMVWT. The tetanus toxoid epitope coding sequence 209 
was introduced in CuMVWT gene, by two step PCR mutagenesis, resulting in expression vector 210 
pET-CuMVtt. For CuMVtt VLPs, E. coli C2566 cells (New England Biolabs, Ipswich, USA) 211 
were transformed with the CuMVtt CP gene-containing plasmid pETCuMVtt. The expression 212 
was induced with 0.2 mM Isopropyl-β-D-thiogalactopyranoside (IPTG). The resulting biomass 213 
was collected by low-speed centrifugation and was frozen at -20 °C. After thawing on ice, the 214 
cells were suspended in the buffer containing 50mM sodium citrate, 5mM sodium borate, 5mM 215 
EDTA, 5mM mercapto-ethanol (pH 9.0, buffer A) and were disrupted by ultrasonic treatment. 216 
Insoluble proteins and cell debris were removed by centrifugation (13,000 rpm, 30 min at 5 °C, 217 
JA-30.50Ti rotor, Beckman, Palo Alto, USA). The soluble CuMVtt CP protein in clarified lysate 218 
was pelleted using saturated ammonium sulfate (1:1, vol/vol) overnight at 4°C. Soluble CuMV-219 
CP-containing protein solution was separated from the cellular proteins by ultracentrifugation in 220 
a sucrose gradient (20–60% sucrose; ultracentrifugation at 25’000 rpm for 6 h at 5 °C (SW28 221 
rotor, Beckman, Palo Alto, USA)). After dialysis of CMV containing gradient fractions, VLPs 222 
were concentrated using ultracentrifuge (TLA100.3 rotor, Beckman, Palo Alto, US; at 72,000 223 
rpm 1 h, +5 oC) or by ultrafiltration using Amicon Ultra 15 (100 kDa; Merck Millipore, Cork, 224 
Ireland). 225 
 226 
Generation of the vaccine CuMVtt-Ara R, CuMVtt-Ara h 1 and CuMVtt-Ara h 2  227 
The peanut extracts, Ara h 1 or Ara h 2 were modified for the subsequent coupling to CuMVtt 228 
VLPs with SATA according to protocol of manufacturer (Thermo Fisher Scientific, Waltham, 229 
MA, USA). SATA reactions were performed for 30 min at 23 °C using 3.6 x molar excess of 230 
SATA for Ara R or 3.3 x for Arah1 and 10 x for Arah202-nhk. Unreacted SATA was removed 231 
by 4-times washing the proteins with 5 mM NaHPO4 Ph 7.5, 2mM EDTA using Amicon Ultra-232 
0.5, 10 K filtration units (Merck-Millipore). Free Sulfhydryl groups in modified proteins were 233 
generated by deacetylation with 0.5 M Hydroxylamine (Thermo Fisher Scientific, Waltham, 234 
MA, USA), incubation for 2 hours at 23°C. The modified peanut extract, Ara h 1 or Ara h 2 were 235 
conjugated to CuMVtt using the cross-linker SMPH (Thermo Scientific, 10-molar excess, 60 min 236 
23 °C). The coupling reactions were performed with 0.3 x molar excess of SATA modified Ara 237 
R, 0.3 x SATA-Arah1 or equal molar amount of Arah202-nhk regarding the CuMVtt (shaking at 238 
23°C for 3 hours at 1200 rpm on DSG Titertek, Flow Laboratories). Unreacted SMPH and 239 
peanut proteins were removed using Amicon-Ultra 0.5, 100K (Merck-Millipore, Burlington, 240 
MA, USA). VLP  samples were centrifuged for 2 minutes at 14000 rpm for measurement on ND-241 
1000. 242 
Due to crosslinking of subunits, derivatization by SMPH leads to the characteristic ladder of 243 
CuMVtt monomers, dimer, trimers, tetramers, etc. The primary coupling band for CuMVtt-Ara h 244 
1 appears as one CuMVtt monomer linked to one Ara h 1 protein at ~110 kDA. Coupling 245 
efficiency was calculated by densitometry (as previously described for IL17A-CMVTT vaccine 246 
(24)) with a result of ~ 20 to 30% meaning 60 peanut allergens molecules were linked to one 247 
particle. 248 
Coupling confirmation and densitometry measurement were achieved on SDS-Page as shown in 249 
Figure 1A. 250 
Mice experiments 251 
BALB/c mice (Envigo, Huntingdon, UK) were purchased at the age of 6 weeks and kept at the 252 
DKF animal facility, Murtenstrasse 31, Bern. All animals were used for experimentation 253 
according to protocols approved by the Swiss Federal Veterinary Office (licence number BE 254 
70/18).  255 
To test the immunogenicity of the vaccines, 6-weeks-old naïve BALB/c mice were immunized 256 
s.c. either with CuMVtt coupled to Ara h 1 (30 µg CtMVtt-Ara h 1) or with Ara h 1 (10 µg). IgG 257 
levels 7 and 14 days after vaccination.  258 
Six-weeks-old naïve BALB/c  mice were sensitized to peanut by injecting twice i.p. with 5 µg 259 
roasted peanut extract mixed in 200 µl Alum (10 mg/ml Al(OH)3; Alhydrogel; InvivoGen, 260 
USA). For efficacy experiments, sensitized mice were vaccinated once s.c. either with 30 µg 261 
CuMVtt-Ara R, CuMVtt-Ara h 1 or CuMVtt-Ara h 2 in 200 µl PBS, 2 weeks after sensitization, 262 
control groups were injected with CuMVtt 30 µg. Challenge was performed i.v., via skin prick 263 
test or gavage. 264 
For induction of anaphylaxis, sensitized mice were challenged i.v. with 20 µg roasted peanut 265 
extract in 200 µl PBS. Temperature was measured with a rectal probe thermometer (Vetronic 266 
Services LTD, Devon UK) before i.v. antigen challenge and monitored for 50 minutes after 267 
challenge. To assess physical fitness and activity after challenge, open field activity tests were 268 
performed starting 10 minutes after i.v. injection. Distance moved was recorded for 10 minutes 269 
for all group and evaluated with the video tracking system EthoVision XT-11 (Noldus 270 
Information Technology, Wageningen, Netherlands).  271 
For passive vaccination, IgG antibodies were induced with CuMVtt-Ara h 1 immunization of 272 
naïve 6-weeks-old BALB/c mice. Pooled serum was collected and IgG isolated through Protein 273 
G sepharose column (GE Healthcare, Chicago, USA; according to manufactures instruction). 274 
Sensitized  mice received once 150 µg of isolated IgGs in 200 µl PBS 24 hours before challenge, 275 
the control group 200 µl PBS. To assess the role of the inhibitory FcγRIIb receptor on basophils 276 
and mast cells on a systemic level, mice were injected i.v. with 150 µg anti-FcγRIIb antibodies 277 
(provided by Cragg M., Antibody and Vaccine Group, Southampton, United Kingdom) 24 hours 278 
before i.v. challenge with peanut extract. At the same time, as a control isotype antibody, 150 µg 279 
anti-Histidin antibodies were injected in CuMVtt-Ara h 1 vaccinated mice.  280 
The local local allergic reaction was assessed by ear prick test. Mice were injected i.v. with 200 281 
ml of Evans blue solution (0.5% in PBS). Afterword a drop of peanut extract solution (180 µg/20 282 
µl PBS) was placed onto the outer ear skin of anesthetized mice. Pricks on the ear skin were 283 
performed with 23G (0.6 mm Å~25 mm) needles (Microlance; BD). To assess FcγRIIb receptor 284 
function, designed ankyrin repeat proteins (DARPins) (27) against mouse FcγRIIb receptor were 285 
used for blocking the receptor by means of local subcutaneous injection on the ears 10 minutes 286 
before the ear prick. Dye extravasations started immediately after antigen challenge. 40 min 287 
later, mice were sacrificed and ears were collected. Ears were collected, photographed with C300 288 
device (Azure Biosystems Dublin, CA, USA) and surface of the blue extravasation was 289 
quantified by Fiji ImageJ software.  290 
The infiltration of eosinophils in the gastrointestinal tract was assessed as follows: Sensitized and 291 
vaccinated mice were challenged for 3 days once per day with 100 mg roasted peanut or PBS via 292 
gavage. Mice were then sacrificed, stomach and proximal jejunum were collected, washed in 293 
PBS, fixed in paraformaldehyde 4% for 4 hours and embedded in paraffin. 5 µm sections were 294 
cut and stained with hematoxylin-eosin. 5 random fields per section (2 for stomach, 3 for 295 
jejunum) were examined with a Imager.M2 (Zeiss, Oberkochen, Germany) Microscope and 296 
scored for infiltration of eosinophils in the lamina propria according to a  morphologic scale (1: 297 
no infiltration of eosinophils, 2: moderate infiltration of eosinophils, 3: strong infiltration of 298 
eosinophils).  299 
For flow-cytometry analysis and eosinophils quantification, the first 10 cm of the small intestine 300 
were collected and mesenteric tissue was removed. The small intestine was longitudinally 301 
opened, washed in Hanks Balanced Salt Solution (HBSS) and cut in small pieces. Epithelial cells 302 
were removed through incubation for 20 min (37°C, on incubator shaker) in 35 ml pre-warmed 303 
HBSS containing 2% horse serum 0,005M EDTA (Sigma-Aldrich,  Saint-Loius, USA) and 304 
0.000308% DTT (Sigma-Aldrich,  Saint-Loius, USA). Then intestinal pieces were washed in 305 
HBSS containing 2% horse serum and digested for 20 min in pre-warmed HBSS containing 2% 306 
horse serum, collagenase IV (50mg/100ml (Sigma-Aldrich,  Saint-Loius, USA)) and DNase1 (2 307 
mg/100 ml, (Roche Diagnostics, Switzerland)) solution (37°C, on incubator shaker). The 308 
resulting suspension was filtered (40 µm pore) and centrifuged for 4 min at 370 g. The pellet was 309 
collected in HBSS containing 2% horse serum and DNase1 (2mg/100ml (Roche Diagnostics, 310 
Switzerland)). For eosinophils detection, cells were stained in HBSS on ice for 30 minutes: 311 
viability dye live/dead fixable blue dead cell stain kit (Invitrogen, Carlsbad, USA), CD45-BV711 312 
(BioLegend, San Diego, USA), CD11b-PE (Becton Dickinson, Franklin Lakes, New Jersey, 313 
USA), Siglec F-PerCpCy5.5 (Becton Dickinson, Franklin Lakes, New Jersey, USA), GR1-314 
AlexaF700 (BioLegend, San Diego, USA). Intestinal mast cells were stained with PE-Cy7-CD45 315 
(BioLegend, San Diego, USA), APC-c-Kit (Becton Dickinson, Franklin Lakes, New Jersey, 316 
USA) and FITC-FcεRI (Thermo Fisher Scientific, Waltham, USA). Measurements were 317 
performed with FACS LSR II (Becton Dickinson, Franklin Lakes, New Jersey, USA) cytometer 318 
and analysis with FlowJo software (FlowJo LCC).  319 
 320 
ELISA for determining peanut specific IgG 321 
96-well Nunc MaxisorpTM ELISA plates (Thermo Fisher Scientific, Waltham, MA, USA) were 322 
coated with 1 µg/ml in carbonate buffer at 4°C overnight. After blocking with PBS/0.15% 323 
Casein solution for 2 hours, plates were washed five times with PBS/0.05% Tween. Serial 324 
dilutions of sera were added to the plates and incubated for 2 hours at 4°C. Plates were then 325 
washed five times with PBS/0.05% Tween (PBST). Thereafter, HRP-labeled goat anti-mouse 326 
IgG (The Jackson Laboratory, Bar Harbor, ME, USA) antibodies were incubated at 4°C for 1 h. 327 
For determination of peanut extract specific IgG subclasses, biotin-labeled mouse anti-mouse 328 
IgG1 (The Jackson Laboratory, Bar Harbor, ME, USA), biotin-labeled mouse anti-mouse IgG2a 329 
(Becton Dickinson, Becton Dickinson, Franklin Lakes, New Jersey, USA) or biotin-labeled rat 330 
anti-mouse IgG2b (BioLegend, San Diego, USA) were used as detection antibodies for 1 hour at 331 
4°C. Thereafter HRP-labelled streptavidin (DakoCytomation, Denmark) was incubated at 4°C 332 
for 1h. ELISAs were developed with TMB (3,30,5,50-tetramethyl- benzidine) and H2O2 and 333 
stopped with 1 mol/L sulfuric acid. Optical densities were measured at 450 nm. Half-maximal 334 
antibody titers are defined as the reciprocal of the dilution leading to half of the OD measured at 335 
saturation. 336 
 337 
ELISA for determining mast cell protease-1 (MCPT-1) 338 
MCPT-1 were measured in serum of mice collected one hour after i.v. challenge. The 339 
experiments were performed according to the manufactures instructions (MCPT-1 Mouse 340 
uncoated ELISA Kit, Invitrogen, Thermo Fisher, US). 341 
 342 
In vivo Reactogenicity of CuMVtt vaccine 343 
Sensitized mice were challenged intravenously two weeks after completed sensitization with 344 
roasted peanut extract 20 µg or CuMVtt-Ara R 60 µg (corresponding dose of free and CuMVtt 345 
bound allergen). Anaphylaxis was assessed measuring temperature every 10 minutes for 50 346 
minutes.To assess local reactogenicity of single major allergens, sensitized mice were challenged 347 
with Ara h 1 or CuMVtt-Ara h 1, in parallel with Ara h 2 and CuMVtt-Ara h 2 (with an allergen 348 
concentration of 0.3 mg/ml). 349 
 350 
In vitro reactogenicity of CuMVtt vaccine, Basophils Activation Assay  351 
Experiments with blood of peanut allergic patients were approved by the local ethics Committee, 352 
KEK-Number 2018-00204. The experiments were performed according to the manufactures 353 
instruction (Flow CAST, Bühlmann, Switzerland). Briefly, whole blood of peanut allergic 354 
patients was incubated with free Ara h 2 or Ara h 2 bound to CuMVtt (same concentration 355 
related to the contained allergen). Basophils were detected with PE-fluorescence labelled anti-356 
CCR3 monoclonal antibody. Cell activation was determined by FITC-fluorescence labelled anti-357 
CD63 monoclonal antibody. Measurements were performed with FACS Canto (BD Biosciences) 358 
flow cytometer and analysis with Flowjow software (FlowJo LCC). 359 
 360 
Simultanoeus binding and co-localization of IgE and IgG on basophils 361 
Whole blood cells from naïve or peanut sensitized mice were incubated after lysing of the 362 
erythrocytes (Lysing buffer, Lonza, Walkersville, USA) with serum of naïve or CuMVtt-Ara h 1 363 
immunized mice (1:5) together with peanut extract (1 µg/ml) in RPMI 164 for 30 min at room 364 
temperature. After washing, cells were stained with anti-mouse IgE-FITC (BD Becton 365 
Dickinson), anti-mouse CD49b-APC (BioLegend, San Diego, USA) and anti-mouse IgG-PE 366 
(Jackson ImmunoResearch, UK). Measurements were performed with FACS Canto (BD 367 
Biosciences) and analysis with FlowJo software (FlowJo LCC). 368 
 369 
Imaging flow cytometry and analysis using Amnis IDEAS software 370 
Imaging flow cytometry was performed using Image Streamx flow cytometer and the compatible 371 
INSPIRE system software (Amnis Corporation, Seattle, Wash). Cells were measured at 40× 372 
magnification and a flow speed flow coefficient below 0.2% indicating a stable core stream. 373 
Single cells were gated on the basis of “area” and “aspect ratio” features of the bright-field 374 
channel, which was set on channel 1. Focused cells were selected on the basis of “gradient root-375 
mean-square” feature that measures the resolution of an image, whereby values above 60 were 376 
considered for further analysis. Basophils were gated based on APC anti-CD49b and FITC anti-377 
IgE intensity. The data was analyzed using the IDEAS software (Amnis Corporation). IgE and 378 
IgG co-localization was assessed in IgG positive basophils using “bright detail similarity” 379 
features of the fluorescence emitted by FITC anti-IgE and PE anti-IgG in the co-localization 380 
wizard provided by the IDEAS software.  381 
 382 
In vitro inhibition of mast cells activation 383 
Murine bone marrow derived mast cells were cultured from BALB/c mice WT, as described in 384 
(28). Cells were sensitized against peanut by incubation with serum derived from peanut 385 
sensitized mice (ratio 1:10 in medium) overnight. After washing, mast cells were challenged 386 
with peanut extract (in a concentration of 1 µg/ml) preincubated with serum of naïve mice or 387 
with serum of CuMVtt-Ara h 1 vaccinated mice (ratio 1:10 in medium) for 30 minutes in the 388 
incubator (37 °C). After washing, cells were stained with anti-CD63-APC  (BioLegend, San 389 
Diego, USA) to detect activation. Measurements were performed with FACS Canto (BD 390 
Biosciences) and analysis with FlowJo software (FlowJo LCC).  391 
 392 
Statistical analysis 393 
Statistical tests were performed with GraphPad PRISM 6.0 (Graph- Pad Software, Inc., La Jolla, 394 
CA, USA). Statistical significance is displayed as P ≤ .05 (*), P ≤ .01 (**), P ≤ .001 (***), P ≤ 395 
.0001 (****).  Groups for IgG levels, dot surface after skin prick test, open field results (distance 396 
moved and velocity) and area under the curve were analyzed by unpaired two-tailed Student’s t-397 
test. Anaphylaxis curves were analyzed by repeated measures two-way-Anova test. 398 
  399 
RESULTS  400 
 401 
Coupling of roasted peanut extract, Ara h 1 or recombinant Ara h 2 to CuMVtt 402 
To generate and test different vaccine-candidates against peanut allergy, we chemically coupled 403 
either the mixture of Ara h allergens contained in the extract of roasted peanut, or the purified 404 
single major allergen Ara h 1 or the recombinant Ara h 2 to the repetitive surface of CuMVtt, 405 
followed by removal of free allergen (supplementary Fig. S1 and S2) (24). Details for the 406 
allergen coupling are shown by SDS-PAGE in Fig. 1A. Densitometric analysis shows a coupling 407 
efficiency of about 20 to 30%. Therefore, approximately 15 to 20 µg of allergens are contained 408 
per 60 µg of vaccine. Fig. 1B shows with Ara h1 as an example that structure of VLPs is 409 
preserved after coupling. 410 
 411 
Vaccination with CuMVtt-Ara R, CuMVtt-Ara h 1 and CuMVtt-Ara h 2 protects against 412 
anaphylaxis 413 
To establish a mouse model for peanut allergy, BALB/c mice were sensitized i.p. at day 0 and 414 
day 7 with 5 µg roasted peanut extract absorbed to Alum. For induction of anaphylaxis, 415 
sensitized mice were challenged i.v. with different doses of roasted peanut extract in 200 µl PBS. 416 
Rectal temperature was assessed at the time point of injection and every 10 minutes for 50 417 
minutes after challenge (Fig.1C). As shown in Fig. 1D the dose-dependent temperature drop as 418 
correlative parameter for anaphylaxis was assessed after allergen challenge. Mice receiving 100 419 
µg peanut extract showed a temperature < 32 °C after 30 min and were euthanized.  420 
To assess whether vaccinated animals were protected against anaphylaxis, BALB/c mice were 421 
vaccinated subcutaneously two weeks after sensitization with a single dose of 30 µg CuMVtt-422 
Ara R, CuMVtt-Ara h 1 or CuMVtt-Ara h 2, or as a control CuMVtt alone (Fig. 2A). S.c. 423 
administration of CuMVtt alone or CuMVtt coupled to the allergens did not induce anaphylactic 424 
reactions in allergic mice, as shown by constant body temperature after injection (data not 425 
depicted). In contrast, s.c. injection with the corresponding amounts of free peanut allergens 426 
induced a significant anaphylactic reaction (supplementary figure S3). 427 
Two weeks after vaccination, all groups were challenged i.v. with 20 µg roasted peanut extract 428 
and body temperature was monitored for 50 minutes (Fig. 2A). Groups immunized with CuMVtt 429 
alone showed a severe drop in body temperature. In contrast, CuMVtt-Ara R, CuMVtt-Ara h 1 430 
and CuMVtt-Ara h 2 vaccinated mice were protected from anaphylactic reactions (Fig. 2B). An 431 
unexpected observation was the observed protection against the whole extract when mice were 432 
vaccinated against single allergens (Ara h 1 and Ara h 2) which allowed us to pursue new lines 433 
of investigation in order to gain better understanding and insights into the potential mechanism 434 
driving protection induced by the vaccine.  435 
To determine the role of mast cells and IgE in the observed anaphylaxis, serum levels of  mast 436 
cell protease 1 (MCPT-1) were measured by ELISA in an exemplary way for mice immunized 437 
against Ara h 1. Fig. 2C shows lower serum levels of mast cell protease 1 (MCPT-1) in the 438 
CuMVtt-Ara h 1 vaccinated group than in mice vaccinated with CuMVtt one hour after i.v. 439 
challenge. These data confirm the protective effect of the vaccine against anaphylaxis. 440 
Furthermore, increased serum MCPT-1 levels in the control group after challenge indicate mast 441 
cells degranulation and IgE-dependent induction of anaphylaxis in this mouse model (in line 442 
with (29)).  443 
 444 
Displaying peanut extract on CuMVtt strongly reduces its reactogenicity 445 
Absence of reactogenicity of a vaccine against peanut allergy plays a fundamental role for 446 
clinical translation, since allergic reactions are feared and potentially dangerous. For this reason, 447 
severely allergic patients are usually excluded from clinical trials for immunotherapy based on 448 
allergens. To address the question of reactogenicity, BALB/c mice were sensitized with peanut 449 
extract and 2 weeks later challenged with 20 µg peanut extract or 60 µg CuMVtt-Ara R 450 
(corresponding to an equivalent amount of allergen present in the challenge). Temperature drop 451 
was extensive in the group challenged with free allergen (peanut extract), whereas animals 452 
challenged with peanut extract coupled to CuMVtt did not show altered temperature (Fig. 2D). 453 
Local reactogenicity was also monitored using skin prick test. In order to visualize extravasation, 454 
mice were pretreated with Evans Blue intravenously before the. Prick test. As shown in  Fig. 2E, 455 
mice challenged with Ara h 1, Ara h 2 and Ara R developed a stronger allergic extravasation 456 
compared to mice challenged with CuMVtt-Ara h 1, CuMVtt-Ara h 2  and CuMVtt-Ara R 457 
respectively (allergen concentration of 0.3 mg/ml).   458 
Next we performed in vitro basophil activation tests (BAT) with whole blood of peanut allergic 459 
donors. We compared expression of CD63, a marker for basophils degranulation, after whole 460 
blood incubation with Ara h 2 or CuMVtt-Ara h 2 in an equivalent concentration to the free 461 
allergen (30 ng/ml). Fig. 2F shows basophil activation upon free allergen stimulation; in contrast, 462 
incubation with Ara h 2 displayed on CuMVtt failed to activate basophils showing CD63 levels 463 
comparable to unstimulated blood. Collectively these results show that displaying peanut 464 
allergens on CuMVtt strongly reduces their reactogenicity. This observation is consistent with 465 
previous experiments performed with the cat allergen Fel d 1 in free form or coupled to Qβ-466 
VLPs (23). 467 
 468 
Immunogenicity of CuMVtt-Ara h 1 in naïve and sensitized mice 469 
Since Ara h 1 could easily be purified in large amounts from peanut extracts, CuMVtt-Ara h 1 470 
was the preferred candidate from a production point of view and we focused subsequent 471 
experiments on this allergen as an exemplary model to explore this observed protection using a 472 
single allergen approach.  473 
To this end, we addressed the immunogenicity of CuMVtt-Ara h 1 in a next step. Naïve BALB/c 474 
mice were immunized s.c. with 10 µg of Ara h 1 either coupled to CuMVtt or in free form. 475 
Peanut extract-specific serum IgG was measured 7 and 14 days after immunization. As seen in 476 
Figure 3A, peanut specific IgG titers were induced by Ara h 1 coupled to CuMVtt whereas 477 
strongly reduced titers were detected upon injection of free Ara h 1. Next, we investigated the 478 
immunogenicity of CuMVtt-Ara h 1 in mice previously sensitized with peanut extract by 479 
measuring IgG-subclass-titers at day 34 (one day before challenge). As shown in Fig. 3B 480 
vaccination with CuMVtt-Ara h 1 led to an increase in peanut extract-specific IgG1, IgG2a and 481 
IgG2b titers compared to basal levels of IgG subclasses in sensitized mice immunized with 482 
CuMVtt. These date indicate that immunization with CuMVtt vaccines has an impact on all IgG 483 
subclasses. 484 
 485 
Passive vaccination with IgG generated with CuMVtt-Ara h 1 protects against anaphylaxis 486 
To investigate the specific role of IgG antibodies in protection against anaphylaxis, BALB/c 487 
mice were injected with CuMVtt-Ara h 1 and IgG antibodies were purified from serum using 488 
protein A. Transfer of 150 µg of total IgG antibodies into peanut-sensitized mice protected from 489 
anaphylactic reactions. Protection was in a similar range as achieved by the vaccine itself, 490 
indicating that IgG antibodies were the major driver of vaccine efficacy (Fig. 3C). 491 
 492 
CuMVtt-Ara h 1 improves  physical fitness of mice after i.v. challenge 493 
Allergic mice challenged i.v. with peanut extract develop typical signs of systemic allergy 494 
including erected hairs and immobility in addition to hypothermia. In order to quantify fitness, 495 
we measured physical activity after challenge in an open field experiment. Effects of vaccination 496 
with CuMVtt-Ara h 1 on distances moved were recorded for 10 minutes, starting 10 minutes 497 
after intravenous peanut extract challenge. As shown in Fig. 4A, vaccination with CuMVtt-Ara h 498 
1 resulted in significantly higher levels of distances the mice moved after challenge compared 499 
with the CuMVtt group, a finding consistent with the protection against temperature drop.  500 
 501 
CuMVtt-Ara h 1 diminishes local mast cell degranulation in skin prick test 502 
To examine the effect of vaccination with CuMVtt-Ara h 1 on local allergic reactions, skin prick 503 
tests were performed in peanut sensitized mice vaccinated with CuMVtt-Ara h 1 or CuMVtt as 504 
control. Allergen challenge by pricking into the ear skin with peanut extract induced vascular 505 
leakage in CuMVtt vaccinated mice. In contrast CuMVtt-Ara h 1 treated animals showed 506 
significantly smaller extravasation surface (Fig. 4B). 507 
 508 
CuMVtt-Ara h 1 reduces infiltration by eosinophils and mast cells in the intestinal tract 509 
after oral challenge 510 
Next, we wanted to address the protective capacity of the vaccine in a model of chronic food 511 
allergy. To this end, we measured the local inflammation in the gastrointestinal tract after gavage 512 
of peanut sensitized mice with ground peanut kernels in PBS. We quantified the infiltration of 513 
eosinophils in the lamina propria of stomach and proximal jejunum after oral challenge for 3 514 
days. 5 random fields per section (2 for stomach, 3 for jejunum) were examined by microscopy 515 
and scored for infiltration of eosinophils in the lamina propria according to a morphologic scale 516 
(as described in (30), 1: no infiltration of eosinophils, 2: moderate infiltration of eosinophils, 3: 517 
strong infiltration of eosinophils). As shown in Fig. 4C eosinophil infiltration in the 518 
hematoxylin-eosin staining is reduced in mice immunized with CuMVtt Ara h 1 compared to 519 
mice treated with CuMVtt alone.  520 
For quantification of eosinophil and mast cells infiltration into the lamina propria of the proximal 521 
small bowel folw cytometry analysis. To this end, 10 cms of the proximal jejunum were 522 
collected, digested and single cell suspensions were stained for cell surface markers. Eosinophils 523 
were defined as living CD45+ CD11b+ SiglecFhigh cells, mast cells were defined as living CD45+ 524 
c-Kit+ FcεRI+ (gating strategy in Supplementary Fig. S3). Fig. 4D shows reduced eosinophil 525 
infiltration (left panel) and mast cells infiltration (right panel) in the CuMVtt-Ara h 1 vaccinated 526 
group which reached levels found in PBS challenged mice.   527 
 528 
The inhibitory FcγRIIb-receptor is required for protection induced by the single allergen-529 
vaccine CuMVtt-Ara h 1 530 
To investigate whether the inhibitory FcγRIIb-receptor present on mast cells and basophils is 531 
involved in protection induced by IgG antibodies generated after CuMVtt-Ara h 1 vaccination, 532 
peanut sensitized BALB/c mice were challenged i.v. 24 hours after injection of an anti-FcγRIIb 533 
mononoclonal antibody (AT 128) to block FcγRIIb-receptor. As shown in Fig. 5A, protection 534 
conferred by vaccination with CuMVtt-Ara h 1 was abrogated by systemic injection of FcγRIIb-535 
blocking antibodies. The protection was not affected when mice were injected with isotype 536 
control IgG. 537 
The involvement of the inhibitory receptor FcγRIIb in protection was confirmed via skin prick 538 
test after locally blocking the FcγRIIb-receptor with an inhibitor molecule (based on DARPin 539 
technology) specific to FcγRIIb (31). As shown above, CuMVtt-Ara h 1 vaccinated mice 540 
developed much smaller extravasation spots after ear skin prick test, but protection was 541 
abrogated by local injection of FcγRIIb-blocking DARPin. Mice with blocked FcγRIIb show a 542 
comparable leakage to unvaccinated challenged mice, demonstrating that inhibitory receptor 543 
FcγRIIb is required for protection (Fig. 5B). 544 
 545 
Protection induced by vaccination is specific for the displayed allergen on CuMVtt 546 
The results so far indicate that vaccination against a single allergen protects against the whole 547 
extract in a FcγRIIb-dependent manner. This implies that immune complexes made of IgG and 548 
allergen are critical for protection. Hence, the vaccines should only work, if the respective 549 
allergens are present in the challenge. To examine this question, we vaccinated peanut sensitized 550 
mice with either CuMVtt or with CuMVtt-Ara h 1 or CuMVtt-Ara h 2 and challenged them in a 551 
skin prick test with the extract, Ara h 1 or Ara h 2 (Fig 5C-E). As expected, mice challenged with 552 
single allergens showed weaker reactions than the ones challenged with the whole extract (data 553 
not shown). We therefore normalized vaccine induced protection to the reaction seen for the 554 
respective allergens used for challenge. As shown in Fig. 5C and D protection was only observed 555 
if mice were challenged with the allergen they were vaccinated against, but not with the other 556 
allergen. In contrast, mice challenged with the extract containing all allergens were protected as 557 
shown in Fig. 5 E. 558 
These results indicate that protection induced by immunization with single allergens is not based 559 
on cross-reactive antibodies but rather on the formation of immune complexes with the 560 
respective allergen used for immunization, causing engagement of the inhibitory FcγRIIb.  561 
 562 
IgE and IgG antibodies binds to basophils simultaneously and show co-localization on the 563 
cell surface 564 
A requisite for the hypothesized mechanism of protection through the inhibitory FcγRIIb 565 
receptor is the simultaneous binding of IgE and IgG-allergen-complexes on basophils and mast 566 
cells. To examine this postulate, we incubated whole blood cells from naïve or peanut sensitized 567 
mice with serum of naïve or CuMVtt-Ara h 1 immunized mice together with peanut extract and 568 
analyzed IgG binding on basophils (CD49b and IgE positive cells were gated) by Flow 569 
Cytometry and Imaging flow cytometry. As shown in Fig. 6A, basophils incubated with serum 570 
derived from CuMVtt-Ara h 1 immunized mice and with peanut extract bind significantly more 571 
IgG than basophils incubated with serum of naïve mice and with peanut extract. In other words, 572 
IgG antibodies induced by the vaccine CuMVtt-Ara h 1 binds on basophils in presence of the 573 
allergen. This effect is significantly increased in basophils derived from peanut sensitized mice 574 
compared to naïve mice, indicating that presence of peanut specific IgE on the cell surfaces 575 
increases binding of IgG-peanut extract complexes. Co-localization of IgE and IgG was highly 576 
significant while there was no co-localization of IgG or IgE with CD49b which is a basophil 577 
surface marker not related to antibody binding (Fig. 6C, D). 578 
 579 
Serum obtained from mice vaccinated with CuMVtt-Ara h 1 inhibits mast cells activation 580 
To confirm in vitro the inhibitory effect of vaccination with CuMVtt-Ara h 1 on mast cells 581 
activation,  bone marrow derived mast cells were first sensitized with serum obtained from 582 
allergic mice. After washing, the challenge was performed with peanut extract preincubated with 583 
serum from mice vaccinated with CuMVtt-Ara h 1 or  CuMVtt-immunized  mice as a control.  584 
As shown in Fig. 6E  mast cell activation was significantly inhibited by the presence of serum 585 
from CuMVtt-Ara h 1 mice confirming the inhibitory effect of IgG-allergen complexes.   586 
587 
DISCUSSION  588 
 589 
 590 
This study uses a preclinical setting to test vaccine candidates for PA. The vaccines are based on 591 
the immunologically optimized plant VLPs CuMVtt coupled either to peanut extract or to the 592 
single major allergens Ara h 1 or Ara h 2.  Vaccination against either Ara h 1 or Ara h 2 was 593 
sufficient to induce protection against the whole peanut extract consisting of multiple allergens, 594 
as assessed in an anaphylaxis model, by skin prick testing and small bowel eosinophils and mast 595 
cells infiltration after gavage. 596 
Efficacy of systemic immunotherapy is thought by some to rely on induction of allergen-specific 597 
regulatory T-cells (32) or a shift from Th2 cells toward Th1 cells (33) with a consecutive 598 
decrease of allergen specific IgE. Induction of humoral responses with generation of allergen 599 
specific IgG during immunotherapy (increasing the ratio IgG/IgE) is discussed by others as an 600 
essential element responsible for induction of allergen-tolerance (34),(35),(36). In this model, 601 
IgG is supposed to both compete with IgE for the allergen preventing crosslinking of the FcεRI 602 
receptor as well as engaging FcγRIIb. A strong “proof of principle” in humans for the protective 603 
effect of allergen specific IgG was obtained through administration of two monoclonal Fel d 1 604 
specific IgG antibodies in cat allergic patients, showing significantly improved symptoms after 605 
nasal stimulation tests in a placebo controlled trial (20). Therefore, a sufficient high titer of IgG 606 
antibodies with adequate affinity/avidity for the allergen is able to diminish allergic symptoms 607 
after exposure. In our study, we found a significant increase of specific IgG responses after 608 
CuMVtt-Ara h 1 immunization and demonstrate that transfer of purified IgG fractions could 609 
confer protection against allergic reactions. This supports the role of IgG in the mechanism of 610 
protection induced by the vaccine candidates tested here. Moreover we could show that IgG was 611 
not anaphylactogenic itself as transfer of IgG from immunized mice did not induce 612 
reactogenicity. This is most likely because high levels of allergens are required for IgG to induce 613 
anaphylactic reactions. A limitation of this study is that some experiments were done by way of 614 
intravenous challenge, which is not physiologic for peanut exposure in humans. Nevertheless as 615 
previously shown (22), parenteral injection of allergen may indeed represent a model for 616 
systemic exposure, allowing investigations of vaccine induced protection against systemic 617 
symptoms and related mechanisms. 618 
We have shown in this study that vaccination against single allergens results in protection against 619 
peanut caused by a complex allergen mixture. Protection was transferrable by IgG antibodies and 620 
the inhibitory receptor FcγRIIb present on mast cells and basophils was critical for reduced 621 
allergic symptoms. Fig. 7 shows a model of the proposed mechanism of action. In allergic 622 
patients, peanut allergens engage IgE molecules on mast cells and basophils, causing their 623 
activation and the allergic response (Fig. 7, left part). In presence of high levels of IgG 624 
antibodies specific for a single allergen, IgG-immune complexes will be formed and bind 625 
FcγRIIb, causing inhibition of all IgE-mediated signals, including those from IgE molecules 626 
cross-linked by other allergens (Fig. 7, right part). This explains why IgG antibodies against 627 
single allergens are able to block cellular activation by whole allergen-extracts. These results are 628 
in line with previous studies showing that FcγRIIb was able to inhibit signals generated by 629 
activating receptors that were sensitized with non-cross-reacting IgE and were not directly co-630 
engaged with FcγRIIb (37). 631 
Patient`s IgE specificities for peanut allergens and even corresponding epitopes can be 632 
determined in most cases. This knowledge will enable to generate a patient specific vaccine 633 
against the most abundant allergen with high IgE but low IgG responses. Potential cross 634 
reactivity may also be taken into account, since different peanut allergens are known to be cross-635 
reactive (38),(39). Hence, some protection against additional allergens may also be caused by 636 
cross-reactivity and regular (cross-reactive) allergen-neutralization. 637 
In summary this study delivers a strong preclinical package for a vaccine using a single-peanut-638 
allergen approach displayed on CuMVtt. It combines an excellent safety profile (absence of 639 
allergic reactions induced by the vaccine) with an equally attractive efficacy profile as 640 
vaccination strongly reduces systemic and local allergic symptoms upon challenge with the 641 
whole allergen extract. Moreover, using our vaccine approach the fact that immunizing against 642 
one single allergen protects against an allergen mixture is striking and could be applied in 643 
different relevant allergies, frequently caused by sensitization against more than one allergen. In 644 
addition PA is an increasing and severe disease, not comparable with many other allergies, hence 645 
we would like to highlight the translational potential of this study.  646 
  647 
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FIGURE LEGENDS  846 
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 848 
Figure 1. 849 
Vaccine generation and establishment of a mouse model of peanut allergy.  850 
A) Analysis of peanut extract, Ara h 1, Ara h 2 and coupling reactions with CuMVtt by SDS 851 
Page 4-12% gradient. Coupling bands show successful reaction. B) Electron microscopy image 852 
of CuMVtt coupled to Ara h 1. Vaccine particles are morphologically not aggregated (for 853 
dynamic light scattering analysis see supplementary Figure S2). C) Experimental design for 854 
establishment of peanut allergy mouse model. 6-weeks-old naïve BALB/c mice were injected i.p. 855 
with 5 µg roasted peanut extract mixed in 200 µl Alum at day 0 and day 7. Challenge with 856 
roasted peanut extract was performed at day 21. D) Temperature after challenge was measured 857 
rectally every 10 minutes for 50 minutes. Dose-dependent anaphylaxis corresponding to 858 
temperature drop after challenge with roasted peanut extract, means +/- SEM are shown (n = 3 859 
mice per group). Data are representative of two independent experiments. Mice showing 860 
temperature < 32°C were euthanized (challenge with 100 µg roasted peanut extract) according to 861 
regulatory protocols. Anaphylaxis curves were analyzed by repeated measures two-way-Anova 862 
test, comparing the PBS challenged group to peanut extract challenged groups (dose dependent 863 
anaphylaxis). 864 
 865 
 866 
867 
Figure 2. 868 
 869 
Vaccine CuMVtt-Ara h 1, CuMVtt-Ara h 2 and CuMVtt-Ara R protect against anaphylaxis in a 870 
mouse model of peanut allergy.  871 
A) To assess efficacy of generated vaccine mice were sensitized with i.p. injection of 5 µg 872 
roasted peanut extract mixed in 200 µl Alum at day 0 and day 7. Mice were vaccinated with 30 873 
µg of CuMVtt-Ara h 1, CuMVtt-Ara h 2 or CuMVtt-Ara R on day 21. Challenge was performed 874 
on day 35 with 20 µg roasted peanut extract. B) Temperature after challenge to assess 875 
anaphylaxis was measured rectally every 10 minutes for 50 minutes. Left panel shows 876 
temperature course after challenge. Means +/- SEM are shown, (n = 4 to 5 mice per group). Data 877 
are representative of 3 independent experiments. Statistical significance was analyzed by two-878 
way-Anova test. Right panel shows statistical analysis performed with unpaired t-test of related 879 
area under the curve (depicted +/- SEM). C) To assess the role of mast cells after challenge in 880 
CuMVtt vaccinated mice compared to CuMVtt-Ara h1 vaccinated mice serum MCPT-1 levels 881 
were measured in ELISA. Data are representative of two independent experiments (depicted +/- 882 
SEM). 883 
D) Displaying allergens on CuMVtt reduces its reactogenicity. To show this, BALB/c mice were 884 
sensitized with peanut extract and 2 weeks later challenged i.v. with 20 µg peanut extract or 60 885 
µg CuMVtt-Ara R (corresponding amount of allergen present in the challenge). To assess local 886 
reactogenicity, sensitized mice were challenged with Ara h 1 or CuMVtt-Ara h 1, in parallel with 887 
Ara h 2 and CuMVtt-Ara h 2 (with an allergen concentration of 0.3 mg/ml). Mean are shown +/- 888 
SEM (n = 3 mice per group), the graph shows results representative of three independent 889 
experiments.  F) Ara h 2 was able to activate in vitro human basophils of peanut allergic patients 890 
(n = 3) in a basophil activation test (BAT, activated basophils defined as CCR3 +, CD63 + cells 891 
by flow cytometry), whereas Ara h 2 coupled to CuMVtt did not activate basophils compared to 892 
unstimulated cells. The experiment was performed once per patient, depicted results are 893 
representative for all 3 patients. 894 
 895 
  896 
Figure 3. 897 
 898 
Immunogenicity of CuMV-Ara h 1.  899 
A) BALB/c mice were injected s.c. either with a total Ara h 1 amount of 10 µg in free form or 900 
coupled to CuMV, left panel. Serum anti-roasted peanut extract IgG levels were measured 7 days 901 
and 14 days post injections. Shown are means +/- SEM (n = 3 mice per group). Data are 902 
representative of 2 independent experiments. Peanut sensitized mice were immunized with 30 µg 903 
CuMVtt or CuMV-Ara h 1 s.c., serum anti roasted peanut extract total IgG were measured at day 904 
34 (one day before challenge), right panel, shown are means +/- SEM (n = 5 mice per group). 905 
Data are representative of 2 independent experiments. B) IgG-subclasses specific for roasted 906 
peanut extract were measured at day 34 (one day before challenge), vaccination with CuMVtt-907 
Ara h 1 led to an increase of OD50 titers of IgG1, IgG2a and IgG2b titers. Means +/- SEM are 908 
shown (n = 4 to 5 mice per group). Data are representative of 3 independent experiments, 909 
statistical analysis was performed with multiple t-test for corresponding dilutions. C) IgG 910 
antibodies were induced with CuMVtt-Ara h 1 immunization of naïve 6-weeks-old BALB/c 911 
mice. Pooled serum was collected from naïve or CuMVtt-Ara h 1 vaccinated mice and IgG-912 
antibodies were isolated through Protein G sepharose column. Sensitized mice received once 150 913 
µg of isolated IgGs from vaccinated mice in 200 µl PBS i.v. 24 hours before challenge, the 914 
control group 150 µg of isolated IgG from naïve mice in 200 µl PBS i.v.. Challenge was 915 
performed with an i.v. injection of 20 µg roasted peanut extract. Means +/- SEM are shown (n = 916 
5 mice per group).  917 
 918 
919 
Figure 4. 920 
 921 
Effects of CuMVtt-Ara h 1 vaccine on physical fitness, skin prick test and on eosinophils 922 
infiltration in the proximal small bowel after challenge with roasted peanut extract in a mouse 923 
model of peanut allergy.  924 
A) Peanut sensitized BALB/c mice were challenged i.v. with 20 µg roasted peanut extract, total 925 
distance moved was measured starting 10 min after i.v. injection for 10 minutes in an open field 926 
experiment. CuMVtt-Ara h 1 increased distance the mice moved after challenge. Mean are 927 
shown +/- SEM.  (n = 9 mice for no challenge group, n = 12 for CuMVtt and CuMVtt-Ara h 1 928 
group). Data are generated with 3 independent experiments. Heatmap plots shows representative 929 
movements of one mouse during 10 minutes of for each group. Statistical analysis of distance 930 
moved is performed with unpaired t-test. B) Sensitized and vaccinated mice were injected i.v. 931 
with 200 ml of Evans blue solution, prick test was performed with peanut extract on the ear skin 932 
under anesthesia. Surface of the extravasation was quantified using Fiji ImageJ software Means 933 
+/- SEM are shown (n = 3 mice per group). Data are representative of 2 independent 934 
experiments. Statistical significance was analyzed by unpaired t-test. C) and D) Sensitized and 935 
vaccinated mice were challenged for 3 days once per day with 100 mg roasted peanut or PBS via 936 
gavage. Mice were then sacrificed, stomach and proximal jejunum was collected. Hematoxylin-937 
Eosin staining (C, arrows: example of eosinophil) and FACS analysis (D) show reduced 938 
eosinophils infiltration (left panel) and mast cells infiltration (right panel) in the lamina propria 939 
of CuMVtt-Ara h 1 vaccinated mice compared to the CuMVtt group. Mean are shown +/- SEM, 940 
data are representative of 2 independent experiments for hematoxylin-eosin sections, (n = 5 mice 941 
per group); FACS analysis regarding the proximal jejunum shows results of one experiment (n = 942 
5 per group for CuMVtt and CuMVtt-Ara h 1 group, n = 3 for PBS challenge).  943 
944 
Figure 5. 945 
 946 
FcγRIIb is required for protection.  947 
A) To assess systemic FcγRIIb receptor function, 150 µg of anti-FcγRIIb monoclonal antibody 948 
(AT 128) were administered i.v. 24 hours before allergen challenge, the control group received 949 
150 µg of isotype IgG. Depicted statistical analysis shows difference between CuMVtt-Ara h 1 + 950 
anti-FcγRIIb and CuMVtt-Ara h 1 + isotype IgG control antibodies (n = 6 mice per group). B) 951 
To assess local FcγRIIb receptor function, a DARPin molecule against FcγRIIb receptor was 952 
used for blocking the receptor by means of local subcutaneous injection on the ears 10 minutes 953 
before the ear prick.  954 
C), D), E) Protection induced by vaccination is specific for the displayed allergen on CuMVtt. 955 
Sensitized BALB/c mice were vaccinated against Ara h 1 or Ara h 2 and challenged in a skin 956 
prick test with the whole extract, Ara h 1 or Ara h2. C) Peanut sensitized mice vaccinated with 957 
CuMVtt-Ara h 1 and challenged with Ara h 1 were protected. In contrast vaccination with 958 
CuMV-tt-Ara h 2 failed to induce protection after challenge with Ara h 1. D) In parallel 959 
vaccination with CuMVtt-Ara h 2 protected in case of challenge with Ara h 2, but vaccination 960 
with CuMV-Ara h 1 failed to protect mice after challenge with Ara h 2. E) CuMVtt-Ara h 1 and 961 
CuMV-Ara h 2 both protect in case of challenge with the whole peanut extract in peanut 962 
sensitized mice  In C-E the vaccine induced protection is shown in % of change to the reference 963 
value obtained for the respective allergen used in the challenge and defined as 100%. Mean are 964 
shown +/- SEM (n = 3 mice per group). Data are representative of 2 independent experiments. 965 
Statistical analysis is performed with t-test. 966 
  967 
Figure 6. 968 
IgE and IgG antibodies bind to basophils simultaneously and show co-localization on the cell 969 
surface. 970 
A) To examine binding of IgE and IgG on basophils, whole blood cells from naïve or peanut 971 
sensitized mice were incubated with serum of naïve or CuMVtt-Ara h 1 immunized mice 972 
together with peanut extract. IgG binding on basophils (CD49b and IgE positive cells were 973 
gated) was quantified by Flow Cytometry (A) and Imaging flow cytometry (B, C, D). Depicted 974 
data (A) were obtained in 3 independent experiments, +/- SEM. B), C), D) Co-localization of IgE 975 
and IgG was assessed in IgG positive basophils of sensitized mice incubated with serum of mice 976 
immunized with CuMVtt-Ara h 1 and peanut extract. Data are shown +/- SEM (n=3 mice per 977 
group). E) Murine bone marrow derived mast cells were sensitized with serum of peanut 978 
sensitized mice. Mast cells were challenged with peanut extract incubated with serum from naïve 979 
or CuMVtt-Ara h 1 vaccinated mice. Activation of mast cells was quantified by Flow Cytometry 980 
gating CD63 positive cells. Data are representative for 3 independent experiments.  981 
 982 
983 
Figure 7.  984 
Protection induced by CuMVtt-Ara h 1 vaccine against peanut allergy, proposed mechanism of 985 
action by which generated anti-Ara h 1 IgG antibodies stimulate the inhibitory receptor FcγRIIb 986 
on mast cells and basophils. FcεRI-meditated degranulation. ITAM, Immunoreceptor tyrosine-987 
based activation motif. ITIM, immunoreceptor tyrosine-based inhibitory motif. SHIP, Src 988 
homology domain 2– containing inositol phosphatase. Syk, spleen tyrosine kinase. Scheme 989 
adapted from (40). 990 
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 1 
Legends Supplementary Figures 2 
 3 
 4 
Supplementary Figure S1.  5 
Characterization of Ara h 1. A) Enrichment of Ara h 1 by ammonium sulfate precipitation (panel 6 
I). Ara h 1 can be enriched by ammonium sulfate  precipitation, most part of Ara h 1 is soluble.  7 
M - protein size marker (Thermo Scientific; #26619);  0 – native peanut extract; AmS - proteins 8 
pelleted with corresponding amount (1.3 – 4 M) of ammonium sulfate; Ex  -  solubilized proteins 9 
from AmS pellets. For Western blots, anti Ara h 1 (panel II) pAbs from Indoor Biotechnologies 10 
were used as primary antibodies, secondary antibodies - HRP-conjugated  antirabbit IgG 11 
produced in goat (Sigma). B) Anion-exchange chromatography of Ara h 1 using Sepharose QHP 12 
column (panel I) SDS-PAGE analysis of Ara h 1 purification (panel II).  M - protein size marker 13 
(Thermo Scientific; #26619); S - start material (peanut extract after precipitation with 4M 14 
ammonium sulfate); 2 - 11 - Sepharose QHP fractions. C) Size-exclusion chromatography of Ara 15 
h 1 using Superdex 200 column (panel I). SDS-PAGE analysis of Ara h 1 purification (panel II).  16 
M - protein size marker (Thermo Scientific; #26619); 2 - 11 - Superdex 200 fractions. D) 17 
Dynamic light scattering analysis of purified Ara h 1. Ara h 1 solution (1 mg/ml) was analyzed 18 
on a Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK). The results of three 19 
measurements were analyzed by DTS software (Malvern, version 6.32). The average 20 
hydrodynamic diameter (Z(av)) was found 18.6 nm. 21 
  22 
Supplementary Figure S2.  23 
 24 
Characterization of Ara h 2. A) SDS-PAGE (panel I) and Western blot (panel II) analysis of 25 
Arah202 inclusion body solubilisation and refolding. M - Protein size marker (Thermo Scientific 26 
Page Ruler Plus, #26619; T – total proteins in recombinant E.coli cells, S – soluble proteins after 27 
corresponding treatment, P – insoluble proteins after corresponding treatment. For Western blot,  28 
the refolded Arah202 was blotted onto nitrocellulose membrane and treated with Ara h 2 pAbs 29 
(Indoor Biotechnologies, produced in rabbits) as primary antibodies; as secondary antibodies 30 
HRP-conjugated antirabbit IgG produced in goat (Sigma) were used. B) Anion-exchange 31 
chromatography of refolded Arah202 using Sepharose QHP column (panel I). SDS-PAGE 32 
analysis of Arah202 purification (panel II).  M - protein size marker (Thermo Scientific; 33 
#26619); 4 - 12 - Sepharose QHP fractions. C) Size-exclusion chromatography of Arah202 using 34 
Superdex 200 column (panel I). SDS-PAGE analysis of Arah202 purification (panel II).  M - 35 
protein size marker (Thermo Scientific; #26619); 3 - 11 - Superdex 200 fractions. D) Dynamic 36 
light scattering analysis of purified Arah202. Arah202 solution (1 mg/ml) was analyzed on a 37 
Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK). The results of three 38 
measurements were analyzed by DTS software (Malvern, version 6.32). The average 39 
hydrodynamic diameter (Z(av)) was found 11.6 nm for most part of the protein. Arah202 40 
partially forms also stable aggregates >100 nm. 41 
42 
Supplementary Figure S3.  43 
A) Gating strategy for flow cytometric quantification of small intestinal lamina propria 44 
eosinophils. Doublets and dead cells were excluded before gating on CD45+ SiglecF+ SSChi 45 
eosinophils. B) Gating strategy for flow cytometric quantification of small intestinal lamina 46 
propria mast cells. Doublets and dead cells were excluded before gating on CD45+ FcRε1+ cKit+ 47 
mast cells. C) Subcutaneous allergen injection induces anaphylaxis. To investigate the effect of 48 
subcutaneous allergen application, mice (n = 3 per group) were injected s.c. with 15 µg dose of 49 
free peanut extract (comparable dose of allergen coupled to the CuMVtt used for vaccination). 50 
After s.c. allergen injection mice develop anaphylactic clinical signs like immobility and erected 51 
hairs and a relevant drop in temperature.   52 
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